Nasus Pharma Ltd
Research Nasus Pharma Ltd (NSRX) on Bullrun: market cap USD 48.01M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNSRX
- ExchangeNYSE MKT
- CountryIsrael
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Market capUSD 48.01M
- Financial periodFY2025
- RevenueUSD 1.24B
- Net income-USD 5.86M
- Free cash flow-USD 4.93M
Valuation Snapshot
latest market cap is USD 48.01M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.24B | -USD 5.86M | -USD 4.93M | n/a | -0.72 | USD 1.24M | USD 118.00K | USD 2.77M |
| FY2024 | n/a | -USD 1.53M | n/a | n/a | -0.22 | USD 284.00K | USD 1.80M | -USD 3.21M |
| FY2023 | n/a | -USD 1.05M | n/a | n/a | -0.2 | USD 193.00K | n/a | -USD 3.80M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 48.01M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 82.49M | n/a | n/a | n/a |
About Nasus Pharma Ltd
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Nasus Pharma Ltd's market cap?
Nasus Pharma Ltd's market capitalization is USD 48.01M.
What does Nasus Pharma Ltd do?
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.